Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Investor Presentation (November 2025)
10 slides from Vitrolife Ab's investor presentation, November 2025
Slide 1: Vitrolife AB (publ) Investor presentation November 2025
Vitrolife AB (publ) Investor presentation November 2025
Slide 2: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Organ
Slide 3: Key IVF market dynamics
Key IVF market dynamics Growth in demand Need to increase IVF capacity & accessibility Clinics labor and skills shortage Automation & digitalization required Consolidation of clinics Standardization and scalability is a must Diverse portfolio to address differences in Regionalisation of standards of
Slide 4: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group M arket Labour Growth in and skills Consoli- Regionali- Patient megatrends demand shortage dation sation Empowerment Our values Vision with a purpose Long-term growth and profit-targets (5 years) Integrity ”Enable people to fulfil the dream of having a healthy baby”
Slide 5: Progress on platform strategy
Progress on platform strategy IVF process Prenatal Pretreatment & Postnatal 5
Slide 6: Well balanced from a portfolio and geographic standpoint
Well balanced from a portfolio and geographic standpoint Consumables APAC 40% 29% Americas 33% Genetics 41% Revenue by Revenue by geography* product groups* EMEA Technologies 38% 19% Good geographic balance has proved critical in Capital sales in Technologies is fluctuating to a the changing macroe
Slide 7: Third quarter 2025
Third quarter 2025 Sales Organic growth in local currencies Gross margin 835 MSEK excluding discontinued business 58.9% (867 MSEK) -4% in SEK +5% (58.6%) impacted by -7% due to currency 3% in local currencies EBITDA Operating cash flow Earnings per share 253 MSEK 255 MSEK 0.75 SEK Margin 30.3% (33.4%
Slide 8: Focus for 2025 – How are we progressing?
Focus for 2025 – How are we progressing? Continue to drive share gain in key markets leveraging the full breadth of the portfolio. Growth Accelerate penetration of our combined EmbryoScope and lab control solutions. Deliver best in class quality and customer service to further differentiate fr
Slide 9: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 10: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there